Endogenous opioid secretion enhancement

"Endogenous opioid secretion enhancement" does **not** refer to a discrete molecular target such as a receptor, enzyme, transporter, or gene product. Instead, it describes the **physiological process** by which endogenous opioid peptides—such as endorphins, enkephalins, and dynorphins—are released from neurons or endocrine cells in response to various stimuli. These peptides act both as neuromodulators within the central nervous system and as hormones in peripheral tissues. They bind to classical opioid receptors (mu-, delta-, kappa-opioid receptors) to mediate effects including analgesia, euphoria/reward signaling, modulation of stress responses, and regulation of cell proliferation in some contexts[1][2][3][4]. The term is not suitable for use as a canonical therapeutic target because it refers broadly to an entire biological pathway rather than an actionable molecular entity. Drugs modulate this system by acting on specific components such as mu-opioid receptors or by influencing precursor synthesis but do not directly "target" the overall process described by this phrase. Therefore: **This entry is incorrect for structured target annotation purposes because it does not represent a single molecule/receptor/protein but rather describes an overall physiological function/pathway.**

Other names

Endogenous opioid systemEndogenous opioid peptidesOpioid peptide secretionEndorphin/enkephalin/dynorphin release (context-dependent)